{"id":127822,"date":"2022-09-30T14:03:56","date_gmt":"2022-09-30T14:03:56","guid":{"rendered":"https:\/\/ccs.ca\/?post_type=news&p=127822"},"modified":"2022-09-30T14:03:57","modified_gmt":"2022-09-30T14:03:57","slug":"two-classes-of-glucose-lowering-drugs-reduce-risk-of-heart-failure-kidney-complications-and-death-even-in-patients-without-type-2-diabetes","status":"publish","type":"news","link":"https:\/\/ccs.ca\/news\/two-classes-of-glucose-lowering-drugs-reduce-risk-of-heart-failure-kidney-complications-and-death-even-in-patients-without-type-2-diabetes\/","title":{"rendered":"Two classes of glucose-lowering drugs reduce risk of heart failure, kidney complications and death \u2013 even in patients without type 2 diabetes"},"content":{"rendered":"\n
New Cardiorenal Protection Guideline urges use of GLP-1RA and SGLT2i drugs to save lives; as many as three million Canadians could benefit.<\/em><\/p>\n\n\n\n Two classes of drugs commonly prescribed to lower glucose levels in people with type 2 diabetes have been shown to reduce hospitalization and death in patients with heart failure and chronic kidney disease, whether they have diabetes or not, according to a new Guideline published in the Canadian Journal of Cardiology<\/em>.<\/p>\n\n\n\n